Reported 9 months ago
Alumis Inc., a clinical stage biopharmaceutical company, raised $250 million in a downsized initial public offering with a concurrent private placement, pricing its shares at the bottom of a marketed range. The California-based company focuses on therapies for patients with immune-mediated diseases, and it is developing two Tyrosine Kinase 2 inhibitor product candidates. Alumis had a net loss of $155 million in 2023 and its IPO was led by Morgan Stanley, Leerink Partners, Cantor Fitzgerald, and Guggenheim Securities, with shares to be traded on the Nasdaq Global Market under the symbol ALMS.
Source: YAHOO